The multichannel generalization of the theory of spectral, scattering, and decay control is presented. New universal algorithms for the construction of complex quantum systems with given properties are suggested. Particularly, transformations of interaction matrices leading to the concentration of w
Cybernetic methods of drug design. I. Statement of the problem—The perceptron approach
✍ Scribed by S.A. Hiller; V.E. Golender; A.B. Rosenblit; L.A. Rastrigin; A.B. Glaz
- Publisher
- Elsevier Science
- Year
- 1973
- Tongue
- English
- Weight
- 591 KB
- Volume
- 6
- Category
- Article
- ISSN
- 0010-4809
No coin nor oath required. For personal study only.
✦ Synopsis
It is revealed that the problem of drug design which is at present coped with on a semiintuitive basis may be. interpreted in terms of modem pattern recognition theory as a problem of discriminating two classes of objects: the active and the inactive chemical compounds.
In the meantime two questions are essentially important: (1) the presentation of information on the structure of a chemical compound, i.e., the elaboration of terms for adequately describing the structure and (2) the selection of a recognition algorithm. This paper deals with the perceptron approach to the resolution of the problem. The structure is, therefore, presented as a sequence of certain coded functional groups and is projected onto the perceptron retina. The error correction procedure with adaptation of S-A connections is employed for classification.
The perceptron approach limitations are examined.
📜 SIMILAR VOLUMES
## Abstract ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract, please click on HTML or PDF.
In this article we represent the development of an artificial-intelligence-based method for the automatic design of valid chemical structures (AISD). The key feature of the proposed algorithm is its ability to mimic many decision-making processes carried by the human drug designer during a design se